Osivax, a clinical-stage biopharmaceutical company focused on innovative influenza vaccines, has partnered with GC Biopharma, a prominent South Korean biopharmaceutical firm known for its expertise in vaccines and plasma-derived products. Together, they aim to develop and commercialize a next-generation seasonal influenza vaccine that promises broader and more enduring protection against a variety of influenza strains.
Collaboration Overview
The collaboration centers around a combination of two vaccine candidates: OVX836 from Osivax and GC FLU from GC Biopharma. OVX836 targets the highly conserved nucleoprotein (NP) of influenza A, while GC FLU is a WHO-prequalified, inactivated seasonal influenza vaccine. By integrating these two approaches into a single injection, the partnership seeks to enhance immune responses and offer more comprehensive protection against both current and emerging influenza strains.
Strategic Licensing Agreement
As part of their agreement, Osivax has secured a non-exclusive, sublicensable global license to use GC FLU alongside OVX836—excluding the markets of Japan and Korea, where GC Biopharma retains exclusive rights. Osivax will spearhead the global development strategy for the combination vaccine, handling its development and commercialization outside South Korea. In return, GC Biopharma will receive royalties and manage the long-term supply of GC FLU. Specific financial details of the agreement have not been disclosed.
Addressing Unmet Needs in Influenza Prevention
Despite significant advancements in influenza vaccination over the decades, the need for improved strategies persists. Alexandre Le Vert, CEO and co-founder of Osivax, emphasizes the importance of this collaboration in developing a superior seasonal influenza vaccine. The combination of Osivax’s T-cell-focused strategy with GC Biopharma’s established manufacturing capabilities represents a pivotal step in addressing unmet needs in seasonal influenza vaccination.
Seasonal Influenza: A Continuing Challenge
Seasonal influenza poses a substantial public health challenge, particularly for older adults and individuals with heightened risk factors. Current vaccines primarily target surface antigens, which can vary greatly from one season to the next. In contrast, OVX836 is designed to focus on NP, a more conserved internal antigen, thereby aiming to provide broader protection across various influenza A strains. Previous studies have demonstrated that co-administering OVX836 with traditional inactivated vaccines is safe and elicits complementary immune responses, paving the way for further exploration of combination strategies.
The Science Behind OVX836
OVX836 stands out as a first-in-class influenza A vaccine candidate, specifically targeting the nucleoprotein (NP). This internal antigen is less prone to mutation compared to surface antigens, allowing for a more universal immune response. Osivax utilizes its proprietary oligoDOM technology to create a recombinant version of NP, which self-assembles into nanoparticles. This innovative approach triggers robust T- and B-cell immune responses. The candidate has undergone seven clinical trials involving over 4,000 participants, yielding encouraging results in terms of safety, immunogenicity, and efficacy.
GC Biopharma’s Established Expertise
GC Biopharma’s seasonal influenza vaccine, GC FLU, is recognized globally, with WHO prequalification affirming its quality and efficacy. The company has been at the forefront of vaccine development for over half a century, and its ongoing commitment to innovation is evident in its investment in research and development in various therapeutic areas, including rare diseases and immunology.
Future Aspirations
Osivax is not only focused on influenza; the company is working to expand its reach into other infectious diseases through strategic collaborations and innovative combinations. With partnerships with esteemed global health organizations and pharmaceutical companies, Osivax is on a mission to combat all forms of seasonal and pandemic influenza.
Conclusion
The collaboration between Osivax and GC Biopharma heralds a promising future for seasonal influenza vaccination. By merging their unique strengths and expertise, they aim to develop a revolutionary vaccine that could significantly enhance public health outcomes. This partnership is a vital step towards creating a more resilient defense against influenza and addressing long-standing challenges in vaccine development.
- Key Takeaways:
- Osivax and GC Biopharma are developing a next-generation influenza vaccine.
- The combination targets both conserved and variable influenza antigens.
- The partnership aims to expand protection against multiple influenza strains.
- OVX836 is based on innovative technology that enhances immune responses.
- GC Biopharma leverages decades of experience in vaccine development.
Read more → www.pharmabiz.com